-
公开(公告)号：US07102001B2
公开(公告)日：2006-09-05
申请号：US11008719
申请日：2004-12-09
申请人： Shankar Swaminathan , Ashvinikumar V. Gavai , Junying Fan , Bharat P. Patel , Derek J. Norris , Richard Michael Corbett , Bin Zheng
发明人： Shankar Swaminathan , Ashvinikumar V. Gavai , Junying Fan , Bharat P. Patel , Derek J. Norris , Richard Michael Corbett , Bin Zheng
IPC分类号： C07D487/14 , C07D413/14 , C07D403/12 , A61K31/53 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides a process for preparing compounds of formula (I) or a pharmaceutically acceptable salt thereof. The compounds prepared by the process of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
摘要翻译： 本发明提供制备式（I）化合物或其药学上可接受的盐的方法。 通过本发明的方法制备的化合物抑制生长因子受体如HER1，HER2和HER4的酪氨酸激酶活性，从而使其可用作治疗癌症和其它疾病的抗增殖剂。
-
2.发明申请FUSED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF NUCLEAR HORMONE RECEPTOR FUNCTION 有权熔化的杂环化合物作为核细胞受体功能的调节剂有用公开(公告)号：US20100331324A1
公开(公告)日：2010-12-30
申请号：US12666423
申请日：2008-06-26
申请人： Derek J. Norris , Ashvinikumar V. Gavai , James Aaron Balog , Joel F. Austin , Weifang Shan , Yufen Zhao , Andrew James Nation , Wen-Ching Han
发明人： Derek J. Norris , Ashvinikumar V. Gavai , James Aaron Balog , Joel F. Austin , Weifang Shan , Yufen Zhao , Andrew James Nation , Wen-Ching Han
IPC分类号： A61K31/5377 , C07D491/18 , A61K31/4035 , C07D401/14 , A61K31/4709 , C07D403/14 , A61K31/506 , C07D413/14 , A61K31/4178 , C07D401/04 , A61K31/4439 , A61P35/00 , A61P17/10
CPC分类号： C07D491/22
摘要： Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
摘要翻译： 公开了式（I）的稠合杂环化合物或其药学上可接受的盐或立体异构体。 还公开了使用这些化合物治疗至少一种雄激素受体相关病症（例如癌症）的方法和包含这些化合物的药物组合物。
-
公开(公告)号：US07064203B2
公开(公告)日：2006-06-20
申请号：US11019899
申请日：2004-12-22
申请人： Ashvinikumar V. Gavai , Wen-Ching Han , Ping Chen , Edward H. Ruediger , Harold Mastalerz , Brian E. Fink , Derek J. Norris
发明人： Ashvinikumar V. Gavai , Wen-Ching Han , Ping Chen , Edward H. Ruediger , Harold Mastalerz , Brian E. Fink , Derek J. Norris
IPC分类号： C07D487/04 , A61K31/53 , A61P19/02
CPC分类号： C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The compounds of the invention inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 本发明的化合物抑制生长因子受体如HER1，HER2和HER4的酪氨酸激酶活性，从而使其可用作治疗癌症和其它疾病的抗增殖剂。
-
公开(公告)号：US07141571B2
公开(公告)日：2006-11-28
申请号：US11019901
申请日：2004-12-22
申请人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
发明人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
IPC分类号： C07D487/04 , A61K31/53
CPC分类号： C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如HER1，HER2和HER4的酪氨酸激酶活性，从而使其成为抗增殖剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
5.发明授权Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith 有权可用作激酶抑制剂的吡咯并嗪化合物及其与激素相关病症的治疗方法公开(公告)号：US07402582B2
公开(公告)日：2008-07-22
申请号：US11475808
申请日：2006-06-27
IPC分类号： C07D487/04 , C07D403/12 , C07D403/14 , A61K31/4155 , A61K31/4162 , A61K31/53 , A61K19/02 , A61K35/00
CPC分类号： C07D487/04
摘要： The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
摘要翻译： 本发明涉及至少一种吡咯并三嗪衍生物，至少一种包含至少一种吡咯并三嗪衍生物的药物组合物和至少一种使用至少一种吡咯并三嗪衍生物以治疗至少一种激酶相关病症的方法。
-
公开(公告)号：US07297695B2
公开(公告)日：2007-11-20
申请号：US11426479
申请日：2006-06-26
申请人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
发明人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
IPC分类号： C07D487/04 , C07D401/06 , C07D401/14 , A61K31/53 , A61P35/00
CPC分类号： C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如HER1，HER2和HER4的酪氨酸激酶活性，从而使其成为抗增殖剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
公开(公告)号：US07846931B2
公开(公告)日：2010-12-07
申请号：US11869910
申请日：2008-09-24
申请人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
发明人： Brian E. Fink , Ashvinikumar V. Gavai , Gregory D. Vite , Ping Chen , Harold Mastalerz , Derek J. Norris , John S. Tokarski , Yufen Zhao , Wen-Ching Han
IPC分类号： A61K31/53 , A61P35/00 , C07D401/06 , C07D401/14
CPC分类号： C07D487/04
摘要： The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of growth factor receptors such as HER1, HER2 and HER4 thereby making them useful as antiproliferative agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.
摘要翻译： 本发明提供式I化合物及其药学上可接受的盐。 式I化合物抑制生长因子受体如HER1，HER2和HER4的酪氨酸激酶活性，从而使其成为抗增殖剂。 式I化合物还可用于治疗与通过生长因子受体操作的信号转导途径相关的其它疾病。
-
8.发明授权Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith 有权可用作激酶抑制剂的吡咯并嗪化合物及其与激素相关病症的治疗方法公开(公告)号：US07405213B2
公开(公告)日：2008-07-29
申请号：US11475816
申请日：2006-06-27
IPC分类号： C07D487/04 , A61K31/53 , A61P19/02 , A61P35/00
CPC分类号： C07D487/04
摘要： The invention relates to at least one pyrrolotriazine derivative, at least one pharmaceutical composition comprising at least one pyrrolotriazine derivative, and at least one method of using at least one pyrrolotriazine derivative to treat at least one kinase associated condition.
摘要翻译： 本发明涉及至少一种吡咯并三嗪衍生物，至少一种包含至少一种吡咯并三嗪衍生物的药物组合物和至少一种使用至少一种吡咯并三嗪衍生物以治疗至少一种激酶相关病症
-
9.发明授权Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3 有权熔融异三环化合物作为17β-羟基类固醇脱氢酶3的抑制剂公开(公告)号：US07378426B2
公开(公告)日：2008-05-27
申请号：US11066407
申请日：2005-02-25
申请人： Ashvinikumar V. Gavai , Derek J. Norris , Wen-Ching Han , Gregory D. Vite , Brian E. Fink , John S. Tokarski
发明人： Ashvinikumar V. Gavai , Derek J. Norris , Wen-Ching Han , Gregory D. Vite , Brian E. Fink , John S. Tokarski
IPC分类号： A01N43/42 , A61K31/44 , C07D487/00 , C07D491/00 , C07D513/00
CPC分类号： C07D471/04 , C07D487/04
摘要： Disclosed are fused heterotricyclic compounds of the following formula I, or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof, wherein one of A ring or C ring is a 5-7 membered unsaturated heterocyclic ring. The disclosed compounds are useful as inhibitors of 17β-hydroxysteroid dehydrogenase 3 (17β-HSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions comprising such compounds.
摘要翻译： 公开了下式I的稠合异三环化合物或其对映体，非对映异构体，互变异构体或其药学上可接受的盐，其中A环或C环之一为5-7元不饱和杂环。 所公开的化合物可用作17β-羟基类固醇脱氢酶3（17β-HSD3）的抑制剂。 还公开了使用这些化合物治疗激素敏感性疾病如前列腺癌的方法和包含这些化合物的药物组合物。
-
10.发明授权Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function 有权稠合杂环化合物可用作核激素受体功能的调节剂公开(公告)号：US08067582B2
公开(公告)日：2011-11-29
申请号：US12666423
申请日：2008-06-26
申请人： Derek J. Norris , Ashvinikumar V. Gavai , James Aaron Balog , Joel F. Austin , Weifang Shan , Yufen Zhao , Andrew James Nation , Wen-Ching Han
发明人： Derek J. Norris , Ashvinikumar V. Gavai , James Aaron Balog , Joel F. Austin , Weifang Shan , Yufen Zhao , Andrew James Nation , Wen-Ching Han
IPC分类号： C07D517/00 , C07D491/00 , A61K31/40
CPC分类号： C07D491/22
摘要： Disclosed are fused heterocyclic compounds of Formula (I) or pharmaceutically-acceptable salts or stereoisomers thereof. Also disclosed are methods of using such compounds in the treatment of at least one androgen receptor-associated condition, such as, for example, cancer, and pharmaceutical compositions comprising such compounds.
摘要翻译： 公开了式（I）的稠合杂环化合物或其药学上可接受的盐或立体异构体。 还公开了使用这些化合物治疗至少一种雄激素受体相关病症（例如癌症）的方法和包含这些化合物的药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.042 秒)
